行业竞争加剧压缩利润空间，国药股份去年及今年首季均陷“增收不增利”困局

读创客户端2025-04-24

深圳商报·读创客户端记者李薇国药股份（600511）4月24日晚间发布2025年一季报，该公司2025年第一季度营收为127.13亿元，同比增长4.87%；归母净利润为4.59亿元，同比下降0.1%；扣非归母净利润为4.46亿元，同比下降2.6%。从数据上看，该公司今年首季业绩并不尽如人意，增收不增利。日前，国药股份公布了2024年年报，2024年实现营业收入为506亿元，同比上升1.8%；归母...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2529293847?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-24 21:12","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2529293847","market":"sh","top_or_hot":-1,"title":"行业竞争加剧压缩利润空间，国药股份去年及今年首季均陷“增收不增利”困局","media":"读创客户端","content":"<div>\n<p>深圳商报·读创客户端记者 李薇国药股份（600511）4月24日晚间发布2025年一季报，该公司2025年第一季度营收为127.13亿元，同比增长4.87%；归母净利润为4.59亿元，同比下降0.1%；扣非归母净利润为4.46亿元，同比下降2.6%。从数据上看，该公司今年首季业绩并不尽如人意，增收不增利。日前，国药股份公布了2024年年报，2024年实现营业收入为506亿元，同比上升1.8%；归母...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504242115329743a261&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>行业竞争加剧压缩利润空间，国药股份去年及今年首季均陷“增收不增利”困局</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n行业竞争加剧压缩利润空间，国药股份去年及今年首季均陷“增收不增利”困局\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-24 21:12 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504242115329743a261&s=b><strong>读创客户端</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>深圳商报·读创客户端记者 李薇国药股份（600511）4月24日晚间发布2025年一季报，该公司2025年第一季度营收为127.13亿元，同比增长4.87%；归母净利润为4.59亿元，同比下降0.1%；扣非归母净利润为4.46亿元，同比下降2.6%。从数据上看，该公司今年首季业绩并不尽如人意，增收不增利。日前，国药股份公布了2024年年报，2024年实现营业收入为506亿元，同比上升1.8%；归母...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504242115329743a261&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0082","symbol_name":"国资改革","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504242115329743a261&s=b","article_id":"2529293847","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504242115329743a261&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2529293847","pubTimestamp":1745500379,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"日前，国药股份公布了2024年年报，2024年实现营业收入为506亿元，同比上升1.8%；归母净利润为20亿元，同比下降6.8%；经营现金流净额为16.59亿元，同比下降39.2%。2024年，国药股份应收账款增加33亿元，存货增加10亿元，应付项增加11亿元，现金流入明显变差。这也对应了国药股份年报经营现金流同比下降39.2%的数据。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600511":"国药股份","BK0082":"国资改革","BK0250":"批发","BK0010":"央企","BK0175":"白马股","BK0097":"医药电商","BK0028":"国家队","BK0185":"二线龙头","BK0188":"融资融券","BK0012":"证金概念"},"translate_title":"Intensifying competition in the industry has compressed profit margins. Sinopharm fell into the dilemma of \"increasing revenue without increasing profits\" last year and in the first quarter of this year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600511":1},"content_text":"深圳商报·读创客户端记者 李薇国药股份（600511）4月24日晚间发布2025年一季报，该公司2025年第一季度营收为127.13亿元，同比增长4.87%；归母净利润为4.59亿元，同比下降0.1%；扣非归母净利润为4.46亿元，同比下降2.6%。从数据上看，该公司今年首季业绩并不尽如人意，增收不增利。日前，国药股份公布了2024年年报，2024年实现营业收入为506亿元，同比上升1.8%；归母净利润为20亿元，同比下降6.8%；经营现金流净额为16.59亿元，同比下降39.2%。具体来看，该公司在医药流通板块，收入小幅增长，但毛利率有所下降。公司表示，2024年医药流通行业在政策、经济、社会和技术等多重因素的影响下，呈现出复杂的发展态势，市场增速呈现放缓趋势，行业竞争加剧，利润空间受到挤压，行业内企业需要不断跟进技术创新、加快转型升级、提升服务质量，满足客户与供应商的多重需求，布局差异化的赛道，从而赢取更大的生存空间。医药工业产品方面，国药股份收入连续三年下降，公司在年报中坦承，报告期内，公司工业板块核心子公司国瑞药业受政策和市场竞争加剧的影响，部分品种价格及销量下滑。公司整体经营面临一定的压力。2024年，国药股份应收账款增加33亿元，存货增加10亿元，应付项增加11亿元，现金流入明显变差。这也对应了国药股份年报经营现金流同比下降39.2%的数据。公司解释经营活动产生的现金流量净额变动原因：2024年受市场环境影响，部分客户回款周期有所延长，带量采购品种付款压力加大，同时资金筹措结构调整所致。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2529293847","isCrawlerRequest":true}